Jade Biosciences, Inc.

JBIO

Jade Biosciences, Inc.

JBIO

Insider Sentiment (TTM):

Last Purchase:2025-05-16Last Sale:2024-06-14Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:49,764,271Shares Outstanding:57,777,165Institutional Ownership Pct.:86.13%

Earnings Market Reaction:

Filing Date:2026-08-10Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Series Seed Convertible Preferred Stock	-	-	0	0	-0	0	0	0	20	-	-	-
Series A Non Voting Convertible Preferred Stock	-	0	0	0	0	-	0	-	-	-	-	-
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	107	55	88	50	221	44	69	31	31	9	23	32
Short Term Investments	354	256	248	149	-	32	0	58	73	90	99	103
Prepaid Expense And Other Assets Current	10	7	13	2	2	1	0	2	7	4	2	2
Assets Current	471	319	349	201	223	77	70	91	111	103	124	138
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	1	1	1	1	1	0	0	0	1	1	1	1
Other Assets Noncurrent	0	0	0	0	0	-	3	0	0	3	2	2
Assets	472	319	350	202	224	78	73	91	112	107	127	141
Liabilities And Stockhold…
Liabilities Current
Operating Lease Liability Current	-	-	-	-	-	0	0	0	0	0	0	0
Accounts Payable Current	7	4	2	1	8	0	1	1	4	3	2	4
Liabilities Current	32	22	17	22	22	2	12	10	17	16	18	15
Other Liabilities	-	-	-	-	-	0	0	0	0	0	0	0
Operating Lease Liability Noncurrent	1	1	1	1	1	-	0	0	0	0	0	0
Liabilities	32	23	17	23	22	2	120	10	17	16	18	15
Stockholders Equity
Preferred Stock Value	-	-	-	0	0	-	-	-	-	-	-	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	711	512	507	322	319	311	0	308	306	278	273	269
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	0	0	-0	0	0	0	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-271	-215	-174	-142	-117	-236	-47	-228	-211	-187	-163	-143
Stockholders Equity	440	296	333	179	202	-84	-47	-17	-0	91	109	126
Liabilities And Stockholders Equity	472	319	350	202	224	78	73	91	112	107	127	141
Preferred Stock Par Or Stated Value Per Share	-	-	-	-	-	0	0	0	0	0	0	0
Related Party	-	0	0	-2	2	-	0	-	-	-	-	-
Preferred Stock Shares Authorized	-	-	-	13	13	10	10	10	10	10	10	10
Preferred Stock Shares Issued	-	-	-	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	-	-	-	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	150	40	150	150	150	150	150
Common Stock Shares Issued	64	49	49	33	33	29	4	29	29	28	28	28
Shares Outstanding	64	49	49	33	33	29	4	29	29	28	28	28
Convertible Long Term Notes Payable	-	-	0	0	-	-	108	-	-	-	-	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-13.13%	-9.17%	-17.09%	-	-	-	-	-	-	-	-	-
2025	-91.96%	-92.60%	-89.26%	6.00%	20.87%	33.70%	26.17%	32.34%	45.89%	-4.70%	77.79%	58.08%
2024	8.36%	-91.59%	-90.96%	10.47%	19.19%	62.21%	0.38%	0.75%	-1.50%	8.70%	-91.49%	-92.17%
2023	-	-	-	-8.43%	-10.17%	-23.28%	38.31%	59.17%	45.70%	-18.18%	-23.67%	-8.65%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	14.93	14.29	21.09	9.01	10.31	32.01	5.81	8.78	6.51	6.65	7.04	9.34
Quick Ratio	14.61	13.96	20.33	8.90	10.22	31.53	5.78	8.60	6.12	6.40	6.94	9.18
Working Capital	439.68M	296.23M	332.28M	179.00M	201.36M	74.96M	57.66M	80.29M	93.74M	87.72M	106.60M	122.88M
Leverage & Debt
Debt to Equity	0.07	0.08	0.05	0.13	0.11	-0.03	-2.56	-0.62	-17,296.00	0.18	0.16	0.12
Interest Coverage TTM	-14.12	-13.01	-14.59	-13.68	-17.59	-20.58	-14.29	-17.79	-13.87	-14.12	-13.69	-14.55
Debt Ratio	0.07	0.07	0.05	0.11	0.10	0.03	1.64	0.12	0.15	0.15	0.14	0.11
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-2.51	-2.24	-4.06	-2.57	-3.29	-19.64	-14.89	-19.35	-20.20	-2.96	-2.87	-2.54
Free Cash Flow Per Share TTM	-1.94	-1.73	-3.03	-1.47	-1.51	-5.61	-7.17	-6.87	-9.67	-2.49	-2.16	-2.06
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	63.88%	109.17%	171.21%	66.76%	46.67%	-24.61%	-37.79%	-12.94%	-0.63%	43.88%	46.61%	47.66%
EPS Growth (1Y)	-23.68%	-88.58%	-72.71%	-86.71%	-83.72%	564.10%	419.09%	662.61%	692.53%	28.26%	36.26%	30.64%
Valuation Metrics
P/E TTM	-8.85	-6.26	-3.80	-3.36	-3.04	-4.36	-6.07	-3.68	-2.80	-341.07	-269.10	-182.40
P/B TTM	3.08	2.74	1.46	1.90	1.41	-3.23	-6.09	-13.34	-178,643.68	308.36	185.67	101.75
Market Cap	1.36B	811.77M	483.88M	341.61M	284.03M	270.12M	285.18M	224.92M	178.64M	28.03B	20.32B	12.79B
Enterprise Value	1.25B	756.68M	395.45M	291.51M	63.09M	225.90M	323.40M	193.80M	147.57M	28.02B	20.30B	12.76B
Calculated Values
Free Cash Flow TTM	-118.25M	-100.21M	-94.89M	-58.29M	-42.91M	-17.70M	-22.61M	-21.67M	-30.51M	-69.15M	-56.92M	-56.93M
Net Debt	-107.25M	-55.09M	-88.44M	-50.11M	-220.94M	-44.22M	38.21M	-31.12M	-31.07M	-9.12M	-23.49M	-32.18M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-05-16Purchase

Owner: Frohlich, Tom

Title: Chief Executive Officer

Shares: 6,000

Price/Share: $7.40

Value: $44,400.00

Shares Owned: 6,000

Relationship: Director,Officer

Ownership: Direct

2024-06-17Purchase

Owner: Shah, Rajeev M., Ra Capit…

Title: -

Shares: 928,110

Price/Share: $1.67

Value: $1,549,943.70

Shares Owned: 7,893,678

Relationship: Director

Ownership: Indirect

2024-06-14Sale

Owner: Eldridge, George A

Title: SEE REMARKS

Shares: 15,000

Price/Share: $25.03

Value: $375,450.00

Shares Owned: 5,022

Relationship: Officer

Ownership: Direct

2024-06-14Sale

Owner: Verwijs, Marinus

Title: CHIEF TECHNICAL OFFICER

Shares: 10,600

Price/Share: $25.00

Value: $265,000.00

Shares Owned: -

Relationship: Officer

Ownership: Direct

2024-06-13Sale

Owner: Gillies, Hunter

Title: CHIEF MEDICAL OFFICER

Shares: 6,000

Price/Share: $24.50

Value: $147,000.00

Shares Owned: 5,602

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-05-16	Frohlich, Tom	Director,Officer	Chief Executive Officer	Direct	Purchase	6,000	7.40	$44,400.00	6,000	4
2024-06-17	Shah, Rajeev M., Ra Capit…	Director	-	Indirect	Purchase	928,110	1.67	$1,549,943.70	7,893,678	4
2024-06-14	Eldridge, George A	Officer	SEE REMARKS	Direct	Sale	15,000	25.03	$375,450.00	5,022	4
2024-06-14	Verwijs, Marinus	Officer	CHIEF TECHNICAL OFFICER	Direct	Sale	10,600	25.00	$265,000.00	0	4
2024-06-13	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	6,000	24.50	$147,000.00	5,602	4
2024-05-17	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	4,000	21.46	$85,840.00	5,602	4
2024-05-16	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,000	21.72	$217,200.00	0	4
2024-05-02	Verwijs, Marinus	Officer	CHIEF TECHNICAL OFFICER	Direct	Sale	1,981	21.02	$41,640.62	0	4
2024-05-01	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	11,357	20.37	$231,342.09	0	4
2024-04-17	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	6,853	23.15	$158,646.95	1,291	4
2024-04-17	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	4,000	22.82	$91,280.00	3,251	4
2024-04-16	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,000	24.67	$246,700.00	0	4
2024-04-10	Eldridge, George A	Officer	SEE REMARKS	Direct	Sale	7,500	27.16	$203,700.00	1,960	4
2024-04-09	Grayzel, David S.	Director	-	Indirect	Sale	11,882	28.15	$334,478.30	14,502	4
2024-04-01	Verwijs, Marinus	Officer	CHIEF TECHNICAL OFFICER	Direct	Sale	5,300	29.44	$156,032.00	0	4
2024-04-01	Eldridge, George A	Officer	SEE REMARKS	Direct	Sale	12,495	31.23	$390,218.85	1,960	4
2024-04-01	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	3,325	31.97	$106,300.25	1,291	4
2024-04-01	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,000	30.46	$304,600.00	0	4
2024-03-28	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	9,000	29.50	$265,500.00	3,251	4
2024-03-27	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	11,068	27.97	$309,571.96	1,291	4
2024-03-25	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	3,432	28.01	$96,130.32	1,291	4
2024-03-19	Verwijs, Marinus	Officer	CHIEF TECHNICAL OFFICER	Direct	Sale	5,300	26.07	$138,171.00	0	4
2024-03-18	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	35,057	26.11	$915,338.27	1,291	4
2024-03-18	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	7,000	26.10	$182,700.00	3,251	4
2024-03-13	Eldridge, George A	Officer	SEE REMARKS	Direct	Sale	2,016	25.02	$50,440.32	1,960	4
2024-03-11	Eldridge, George A	Officer	SEE REMARKS	Direct	Sale	3,433	25.78	$88,502.74	1,960	4
2024-03-07	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	8,975	24.50	$219,887.50	3,251	4
2024-02-23	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	511	19.50	$9,964.50	3,251	4
2024-02-20	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	3,489	20.34	$70,966.26	3,251	4
2024-02-05	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	4,600	17.45	$80,270.00	1,609	4
2024-01-17	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	4,000	19.50	$78,000.00	3,251	4
2024-01-05	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	4,600	19.12	$87,952.00	1,609	4
2023-12-27	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	125	24.50	$3,062.50	3,251	4
2023-12-20	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	4,000	19.50	$78,000.00	3,251	4
2023-12-14	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	9,897	19.50	$192,991.50	3,251	4
2023-12-06	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	10,283	16.11	$165,659.13	1,291	4
2023-12-05	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	4,600	16.30	$74,980.00	1,609	4
2023-11-27	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	12,517	16.24	$203,276.08	1,291	4
2023-11-24	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	4,990	15.90	$79,341.00	1,291	4
2023-11-22	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	13,800	15.00	$207,000.00	1,609	4
2023-11-01	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	1,092	10.42	$11,378.64	0	4
2023-11-01	Verwijs, Marinus	Officer	CHIEF TECHNOLOGY OFFICER	Direct	Sale	970	10.46	$10,146.20	0	4
2023-09-06	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	3,931	15.06	$59,200.86	1,291	4
2023-08-07	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	10,283	15.86	$163,088.38	1,291	4
2023-07-28	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	5,478	18.00	$98,604.00	0	4
2023-07-17	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	4,522	18.11	$81,893.42	0	4
2023-07-06	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	10,283	16.66	$171,314.78	1,291	4
2023-07-05	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,250	17.55	$39,487.50	1,609	4
2023-07-03	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	10,000	18.00	$180,000.00	0	4
2023-06-06	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	10,283	16.63	$171,006.29	1,291	4
2023-06-05	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,250	16.26	$36,585.00	1,609	4
2023-05-19	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	65	19.50	$1,267.50	3,251	4
2023-05-17	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	1,090	19.59	$21,353.10	3,251	4
2023-05-08	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	10,284	22.18	$228,099.12	1,291	4
2023-05-05	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,250	21.21	$47,722.50	1,609	4
2023-05-03	Verwijs, Marinus	Officer	SENIOR VICE PRESIDENT, CMC	Direct	Sale	759	20.79	$15,779.61	0	4
2023-05-02	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	693	21.15	$14,656.95	0	4
2023-04-21	Gillies, Hunter	Officer	CHIEF MEDICAL OFFICER	Direct	Sale	4,000	19.50	$78,000.00	1,960	4
2023-04-06	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	10,283	18.17	$186,842.11	0	4
2023-04-05	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,250	18.51	$41,647.50	1,609	4
2023-04-03	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	15,000	19.46	$291,900.00	0	4
2023-03-06	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,250	24.33	$54,742.50	1,609	4
2023-03-06	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	10,282	24.10	$247,796.20	0	4
2023-03-01	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	15,000	24.22	$363,300.00	0	4
2023-02-06	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	10,284	24.77	$254,734.68	0	4
2023-02-06	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,250	24.27	$54,607.50	1,609	4
2023-02-01	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	15,000	22.78	$341,700.00	0	4
2023-01-06	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	10,284	26.28	$270,263.52	0	4
2023-01-05	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,250	26.40	$59,400.00	1,609	4
2023-01-03	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	15,000	28.32	$424,800.00	0	4
2022-12-12	Eldridge, George A	Officer	SEE REMARKS	Direct	Sale	10,000	30.04	$300,400.00	1,960	4
2022-12-12	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	2,059	28.30	$58,269.70	0	4
2022-12-09	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	394	25.03	$9,861.82	0	4
2022-12-08	Eldridge, George A	Officer	SEE REMARKS	Direct	Sale	12,011	21.63	$259,797.93	1,960	4
2022-12-06	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	40,000	17.15	$686,000.00	0	4
2022-12-05	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,250	17.38	$39,105.00	1,609	4
2022-12-01	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	15,000	18.00	$270,000.00	0	4
2022-11-30	Eldridge, George A	Officer	SEE REMARKS	Direct	Sale	85	19.06	$1,620.10	1,960	4
2022-11-23	Eldridge, George A	Officer	SEE REMARKS	Direct	Sale	1,261	19.07	$24,047.27	1,960	4
2022-11-22	Eldridge, George A	Officer	SEE REMARKS	Direct	Sale	174	19.01	$3,307.74	1,960	4
2022-11-11	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	6,198	21.33	$132,203.34	0	4
2022-11-08	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	8,373	18.09	$151,467.57	0	4
2022-11-07	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,250	18.80	$42,300.00	1,609	4
2022-11-02	Verwijs, Marinus	Officer	SENIOR VICE PRESIDENT, CMC	Direct	Sale	1,130	18.89	$21,345.70	0	4
2022-11-01	Noyes, Timothy P	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	1,038	19.50	$20,241.00	0	4
2022-10-18	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	5,705	21.08	$120,261.40	0	4
2022-10-17	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	4,185	20.16	$84,369.60	0	4
2022-10-10	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	4,954	17.00	$84,218.00	0	4
2022-10-07	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	10,520	16.17	$170,108.40	0	4
2022-10-05	Niven, Ralph	Officer	CHIEF SCIENTIFIC OFFICER	Direct	Sale	2,250	15.96	$35,910.00	1,609	4
2022-09-12	Dake, Benjamin T	Officer	SEE REMARKS	Direct	Sale	7,520	17.98	$135,209.60	0	4
2022-09-09	Dake, Benjamin T	Officer	See Remarks	Direct	Sale	4,720	18.02	$85,054.40	0	4
2022-09-07	Dake, Benjamin T	Officer	See Remarks	Direct	Sale	3,663	18.27	$66,914.97	0	4
2022-09-06	Niven, Ralph	Officer	Chief Scientific Officer	Direct	Sale	2,250	19.00	$42,750.00	1,609	4
2022-08-18	Niven, Ralph	Officer	Chief Scientific Officer	Direct	Sale	2,250	21.18	$47,655.00	1,609	4
2022-08-16	Dake, Benjamin T	Officer	See Remarks	Direct	Sale	21,000	23.28	$488,880.00	0	4
2022-08-11	Dake, Benjamin T	Officer	See Remarks	Direct	Sale	1,347	24.22	$32,624.34	0	4
2022-08-09	Dake, Benjamin T	Officer	See Remarks	Direct	Sale	8,700	24.18	$210,366.00	0	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

86.13%

Inst. Shares: 49,764,271

Shares Outstanding: 57,777,165

2025-12-31

144.92%

Inst. Shares: 45,448,409

Shares Outstanding: 31,359,958

2025-09-30

79.83%

Inst. Shares: 31,601,060

Shares Outstanding: 39,584,489

2025-06-30

109.97%

Inst. Shares: 31,264,861

Shares Outstanding: 28,431,158

2025-03-31

Inst. Shares: 31,659,148

Shares Outstanding: 3,155,500

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	49,764,271	57,777,165	86.13%
2025-12-31	45,448,409	31,359,958	144.92%
2025-09-30	31,601,060	39,584,489	79.83%
2025-06-30	31,264,861	28,431,158	109.97%
2025-03-31	31,659,148	3,155,500	-
2024-12-31	29,958,003	3,155,500	-
2024-09-30	26,810,698	3,155,500	-
2024-06-30	26,808,213	3,155,500	-
2024-03-31	28,403,204	27,795,827	102.19%
2023-12-31	28,122,981	26,331,630	106.80%
2023-09-30	28,381,993	27,640,542	102.68%
2023-06-30	28,387,939	25,166,505	112.80%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Jade Biosciences, Inc. (JBIO) — SEC Financial Statements & Analysis

Jade Biosciences, Inc. (JBIO) is a pharmaceutical preparations company, incorporated in DE. Jade Biosciences, Inc. trades on Nasdaq as: JBIO. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Jade Biosciences, Inc. reported a Debt-to-Equity ratio of 0.07x, a Price-to-Book (P/B) ratio of 3.08x (TTM), at a market cap of $1.36B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.07x
P/B TTM: 3.08x
Market Cap: $1.36B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Jade Biosciences, Inc. in?

Jade Biosciences, Inc. (JBIO) operates in the Pharmaceutical Preparations industry.

What is JBIO's market cap?

Jade Biosciences, Inc. (JBIO) has a market capitalization of $1.36B as of 2026-06-30.

What exchange does JBIO trade on?

Jade Biosciences, Inc. (JBIO) trades on the Nasdaq.

Where is Jade Biosciences, Inc. incorporated?

Jade Biosciences, Inc. is incorporated in DE.